Tumor hypoxia: a target for selective cancer therapy.
Tumor hypoxia has been considered to be a potential therapeutic problem because it renders solid tumors more resistant to sparsely ionizing radiation (IR) and chemotherapeutic drugs. Moreover, recent laboratory and clinical data have shown that tumor hypoxia is also associated with a more malignant phenotype and poor survival in patients suffering from various solid tumors. Therefore, selective targeting of hypoxic tumor cells has been explored, and since severe hypoxia (pO(2) < 0.33%, 2.5 mmHg) does not occur in normal tissue, tumor hypoxia could be exploited for therapeutic advantage. However, the following three characteristics of hypoxic tumor regions present obstacles in targeting hypoxic cells. First, it is difficult to deliver a sufficient amount of drug to a region that is remote from blood vessels. Second, one must specifically target hypoxic tumor cells while sparing normal well-oxygenated tissue from damage. Finally, the severely hypoxic tumor cells to be attacked have often stopped dividing. Therefore, high delivery efficiency, high specificity and selective cytotoxicity are all necessary to target and combat hypoxic tumor cells. The current review describes progress on the biological aspects of tumor hypoxia and provides a compilation of the recent molecular approaches used to target hypoxic tumors. These approaches include our work with a unique hypoxia-targeting protein drug, TOP3, with which we have sought to address the above three difficulties.
Kizaka-Kondoh
Shinae
S
Department of Molecular Oncology, Kyoto University Graduate School of Medicine, 54 Shongoin Kawahararcho, Sakyo-ku, Kyoto 606-8507.
Inoue
Masahiro
M
Harada
Hiroshi
H
Hiraoka
Masahiro
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015687:Cell Hypoxia; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D051793:Hypoxia-Inducible Factor 1; D009369:Neoplasms / Q000098:blood supply* / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D051793:Hypoxia-Inducible Factor 1; D011993:Recombinant Fusion Proteins; C498363:TOP3 fusion protein